Home/Pipeline/KIT2014

KIT2014

Cystic Fibrosis

Phase 2Active

Key Facts

Indication

Cystic Fibrosis

Phase

Phase 2

Status

Active

Company

Kither Biotech

About Kither Biotech

Kither Biotech is a private, clinical-stage company developing inhaled therapies for rare respiratory diseases with high unmet need, notably cystic fibrosis and idiopathic pulmonary fibrosis. Its lead asset, KIT2014, an orphan drug-designated dual PDE3/4 inhibitor peptide, successfully completed Phase 1 in 2025, with Phase 2 planned for 2026. The company has raised significant venture capital, including a €5.6M Series A and an €18.5M Series B in 2022, to advance its pipeline and is built on strong academic roots from the University of Turin.

View full company profile

Therapeutic Areas

Cystic Fibrosis Idiopathic Pulmonary Fibrosis Chronic Obstructive Pulmonary Disease Non-Cystic Fibrosis Bronchiectasis

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
CBN-101	Carbon Biosciences	Preclinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active